Grifols (NASDAQ:GRFS) Rating Lowered to Buy at Wall Street Zen

Grifols (NASDAQ:GRFS) was downgraded by stock analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating in a research report issued to clients and investors on Saturday.

GRFS has been the subject of several other research reports. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Grifols in a report on Wednesday, October 8th. JPMorgan Chase & Co. boosted their price objective on shares of Grifols from $7.60 to $10.30 and gave the company a “neutral” rating in a report on Tuesday, June 17th. Deutsche Bank Aktiengesellschaft reissued a “hold” rating on shares of Grifols in a report on Tuesday, August 5th. Finally, Zacks Research raised shares of Grifols to a “hold” rating in a report on Friday, August 8th. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $10.30.

Grifols Stock Performance

Shares of GRFS stock opened at $9.32 on Friday. The company has a market capitalization of $6.41 billion, a price-to-earnings ratio of 7.97, a PEG ratio of 0.32 and a beta of 0.69. The company has a debt-to-equity ratio of 1.20, a quick ratio of 0.95 and a current ratio of 2.64. The company has a 50-day simple moving average of $10.02 and a 200 day simple moving average of $8.90. Grifols has a 52 week low of $6.19 and a 52 week high of $11.14.

Institutional Trading of Grifols

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Brandes Investment Partners LP lifted its holdings in shares of Grifols by 8.9% during the 2nd quarter. Brandes Investment Partners LP now owns 28,035,461 shares of the biotechnology company’s stock worth $253,441,000 after acquiring an additional 2,294,113 shares during the period. Goldman Sachs Group Inc. lifted its holdings in shares of Grifols by 1.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 4,212,032 shares of the biotechnology company’s stock worth $29,948,000 after acquiring an additional 80,507 shares during the period. Bank of America Corp DE lifted its holdings in shares of Grifols by 52.1% during the 2nd quarter. Bank of America Corp DE now owns 3,017,675 shares of the biotechnology company’s stock worth $27,280,000 after acquiring an additional 1,034,229 shares during the period. New York State Common Retirement Fund lifted its holdings in shares of Grifols by 50.5% during the 1st quarter. New York State Common Retirement Fund now owns 2,452,728 shares of the biotechnology company’s stock worth $17,439,000 after acquiring an additional 823,456 shares during the period. Finally, Sei Investments Co. lifted its holdings in shares of Grifols by 11.6% during the 2nd quarter. Sei Investments Co. now owns 2,081,535 shares of the biotechnology company’s stock worth $18,817,000 after acquiring an additional 216,793 shares during the period.

About Grifols

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.